摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-Bromobenzyloxy)-2,6-bis(chloromethyl)pyridine | 227457-57-0

分子结构分类

中文名称
——
中文别名
——
英文名称
3-(4-Bromobenzyloxy)-2,6-bis(chloromethyl)pyridine
英文别名
3-[(4-Bromophenyl)methoxy]-2,6-bis(chloromethyl)pyridine
3-(4-Bromobenzyloxy)-2,6-bis(chloromethyl)pyridine化学式
CAS
227457-57-0
化学式
C14H12BrCl2NO
mdl
——
分子量
361.065
InChiKey
DMOAQMZDWPQCAW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    19
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    3-(4-Bromobenzyloxy)-2,6-bis(chloromethyl)pyridine 在 lithium hydroxide 、 potassium carbonate巯基乙酸 作用下, 以 乙醇N,N-二甲基甲酰胺乙腈 为溶剂, 反应 26.0h, 生成 12-(4-Bromobenzyloxy)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid
    参考文献:
    名称:
    Contrast Agents for Magnetic Resonance Imaging: A Novel Route to Enhanced Relaxivities Based on the Interaction of a GdIII Chelate with Poly-β-cyclodextrins
    摘要:
    This study proposes a novel route to improved contrast agents for magnetic resonance imaging (MRI) applications based on the formation of a non-covalent adduct between a paramagnetic complex and an exogeneous macromolecule. For this purpose a 12-membered pyridine-containing triacetate macrocyclic ligand with a p-bromo-benzyloxy substituent on the pyridine moiety was synthesized. The Gd-III complex containing this ligand shows a relaxivity of 8.25 mM(-1)s(-1) at 20 MHz and 25 degrees C The hydrophobic p-bromo-benzyloxy moiety promotes the interaction of the chelate with human serum albumin (HSA) (K-a = 4 x 10(2) M-1) and with beta-cyclodextrin (K-a = 8 x 10(2) M-1). Upon replacing beta-cyclodextrin with a poly-beta-cyclodextrin substrate (MW = ca. 6000 Da) a further relaxation enhancement is detected as a consequence of the increased molecular size of the resulting inclusion compound. In a typical experiment in blood serum, the observed relaxivity is 32 mM(-1) s(-1) (20 MHz, 25 degrees C) when the concentrations are as follows: Gd-III chelate 1 mM, poly-beta-cyclodextrin 10 mM, HSA 0.58 mM. Under these conditions the Gd-III chelate is mainly present as an inclusion compound with the poly-beta-CD. This finding suggests a potential use for such a Gd-III chelate/poly-beta-CD system in MR angiographic applications.
    DOI:
    10.1002/(sici)1521-3765(19990401)5:4<1253::aid-chem1253>3.0.co;2-i
  • 作为产物:
    描述:
    3-(4-Bromobenzyloxy)-2,6-bis(hydroxymethyl)pyridine 在 四氯化碳三丁基膦 作用下, 反应 4.0h, 以80%的产率得到3-(4-Bromobenzyloxy)-2,6-bis(chloromethyl)pyridine
    参考文献:
    名称:
    Contrast Agents for Magnetic Resonance Imaging: A Novel Route to Enhanced Relaxivities Based on the Interaction of a GdIII Chelate with Poly-β-cyclodextrins
    摘要:
    This study proposes a novel route to improved contrast agents for magnetic resonance imaging (MRI) applications based on the formation of a non-covalent adduct between a paramagnetic complex and an exogeneous macromolecule. For this purpose a 12-membered pyridine-containing triacetate macrocyclic ligand with a p-bromo-benzyloxy substituent on the pyridine moiety was synthesized. The Gd-III complex containing this ligand shows a relaxivity of 8.25 mM(-1)s(-1) at 20 MHz and 25 degrees C The hydrophobic p-bromo-benzyloxy moiety promotes the interaction of the chelate with human serum albumin (HSA) (K-a = 4 x 10(2) M-1) and with beta-cyclodextrin (K-a = 8 x 10(2) M-1). Upon replacing beta-cyclodextrin with a poly-beta-cyclodextrin substrate (MW = ca. 6000 Da) a further relaxation enhancement is detected as a consequence of the increased molecular size of the resulting inclusion compound. In a typical experiment in blood serum, the observed relaxivity is 32 mM(-1) s(-1) (20 MHz, 25 degrees C) when the concentrations are as follows: Gd-III chelate 1 mM, poly-beta-cyclodextrin 10 mM, HSA 0.58 mM. Under these conditions the Gd-III chelate is mainly present as an inclusion compound with the poly-beta-CD. This finding suggests a potential use for such a Gd-III chelate/poly-beta-CD system in MR angiographic applications.
    DOI:
    10.1002/(sici)1521-3765(19990401)5:4<1253::aid-chem1253>3.0.co;2-i
点击查看最新优质反应信息

文献信息

  • Diethoxyphosphoryl as a Protecting-Activating Group in the Synthesis of Polyazacyclophanes
    作者:Andrea Chellini、Roberto Pagliarin、Giovanni B. Giovenzana、Giovanni Palmisano、Massimo Sisti
    DOI:10.1002/(sici)1522-2675(20000412)83:4<793::aid-hlca793>3.0.co;2-3
    日期:2000.4.12
    The fully diethoxyphosphoryl(Dep)-protected polyamines 1b-3b were prepared from the corresponding polyamines with 'diethyl phosphite' (= diethyl phosphonate) and CCl4 in a solid base/organic liquid two-phase system in the presence of Bu4NBr as phase-transfer catalyst. Subsequent phase-transfer-catalyzed alkylation of phosphoramidates 1b-3b with bis(chloromethyl)arenes 5-8 in the presence of Bu4N(HSO4) followed by deprotection gave good yields of polyazacyclophanes 9a-16a.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (反式)-4-壬烯醛 (双(2,2,2-三氯乙基)) (乙腈)二氯镍(II) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (±)17,18-二HETE (±)-辛酰肉碱氯化物 (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (s)-2,3-二羟基丙酸甲酯 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 ([2-(萘-2-基)-4-氧代-4H-色烯-8-基]乙酸) ([1-(甲氧基甲基)-1H-1,2,4-三唑-5-基](苯基)甲酮) (Z)-5-辛烯甲酯 (Z)-4-辛烯醛 (Z)-4-辛烯酸 (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-氨氯地平-d4 (S)-氨基甲酸酯β-D-O-葡糖醛酸 (S)-8-氟苯并二氢吡喃-4-胺 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(((2,2-二氟-1-羟基-7-(甲基磺酰基)-2,3-二氢-1H-茚满-4-基)氧基)-5-氟苄腈 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯